Patients with multiple myeloma are living longer, thanks to a host of new immunotherapies and targeted drugs. But there is ...

Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of multiple myeloma outcomes and their multifactorial nature. In part 3 of our ...

Bispecific antibodies have been big news for several years at the American Society of Hematology Annual Meeting & Exposition ...

A high-fiber, plant-based diet delays progression to multiple myeloma, improves microbiome health, reduces inflammation, and ...

GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...

The prevailing treatment paradigm for newly diagnosed multiple myeloma (NDMM) patients who have received autologous stem cell transplantation (SCT) primarily consists of chemotherapy or Johnson & ...

Myeloma specialist Dr. Urvi Shah is researching the role that whole-food and plant-based diets may play in slowing the progression of certain conditions into multiple myeloma. Many people who are ...

ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...

Teclistamab is an off-the-shelf (or ready to use) bispecific antibody. 6 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®▼ (teclistamab) from two investigational studies in patients with newly diagnosed ...